Clinical trial · Interventional
Safety Study of SGN-CD70A in Cancer Patients
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
NCT02216890CI-TRIAL-00032594completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will examine the safety profile of SGN-CD70A. The study will test increasing doses of SGN-CD70A given every 3 weeks (or an alternate dosing schedule up to every 6 weeks) to small groups of patients. The goal is to find the highest dose of SGN-CD70A that can be given to patients without causing unacceptable side effects. The pharmacokinetics and antitumor activity of SGN-CD70A will also be evaluated.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse, Large B-Cell, Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
| Follicular Lymphoma, Grade 3 | Grade 3 Follicular Lymphoma | ALIAS | 0.90 |
| Mantle-Cell Lymphoma | Mantle Cell Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SGN-CD70A | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- SGN-CD70A
- interventionNames
- Drug: SGN-CD70A
Primary outcomes (2)
- measure
- Incidence of adverse events
- timeFrame
- Through 1 month following last dose
- measure
- Incidence of laboratory abnormalities
- timeFrame
- Through 1 month following last dose
Secondary outcomes (5)
- measure
- Blood concentrations of SGN-CD70A and metabolites
- timeFrame
- Through 3 to 6 weeks after dosing
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Metastatic renal cell carcinoma, mantle cell lymphoma, or diffuse large B-cell lymphoma including Grade 3b follicular lymphoma * Relapsed, refractory, or progressive disease following at least 2 prior systemic therapies * Confirmed positive CD70 expression on tumor tissue * Eastern Cooperative Oncology Group performance status 0 or 1 * Adequate baseline hematologic, pulmonary, renal, and hepatic function * Measurable disease Exclusion Criteria: * Prior treatment with anti-CD70 directed therapy unless CD70 expression is confirmed on tumor tissue obtained after the treatment * Patients \<100 days since prior allogeneic stem cell transplant * Less than 4 weeks since prior treatment; or 2 weeks if patient experienced disease progression on the prior treatment
References
Publications (0)
Data not yet available
No reference posted for this study.